Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
- PMID: 22337996
- DOI: 10.1158/0008-5472.CAN-11-2957
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
Abstract
The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, mRNA vaccines need to deliver activation stimuli in addition to TAAs to dendritic cells (DC). In this study, we evaluated whether intranodal delivery of TAA mRNA together with TriMix, a mix of mRNA encoding CD40 ligand, constitutive active Toll-like receptor 4 and CD70, results in the in situ modification and maturation of DCs, hence, priming of TAA-specific T cells. We showed selective uptake and translation of mRNA in vivo by lymph node resident CD11c(+) cells. This process was hampered by codelivery of classical maturation stimuli but not by TriMix mRNA. Importantly, TriMix mRNA induced a T-cell-attracting and stimulatory environment, including recruitment of antigen-specific CD4(+) and CD8(+) T cells and CTLs against various TAAs. In several mouse tumor models, mRNA vaccination was as efficient in CTL induction and therapy response as vaccination with mRNA-electroporated DCs. Together, our findings suggest that intranodal administration of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination strategy.
©2012 AACR.
Similar articles
-
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417017
-
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10. J Immunol. 2013. PMID: 23842750
-
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.Cancer Immunol Res. 2016 Feb;4(2):146-56. doi: 10.1158/2326-6066.CIR-15-0163. Epub 2015 Dec 11. Cancer Immunol Res. 2016. PMID: 26659303
-
Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA.Methods Mol Biol. 2013;969:247-74. doi: 10.1007/978-1-62703-260-5_16. Methods Mol Biol. 2013. PMID: 23296939 Review.
-
Challenges and advances towards the rational design of mRNA vaccines.Trends Mol Med. 2013 Dec;19(12):705-13. doi: 10.1016/j.molmed.2013.09.002. Epub 2013 Oct 15. Trends Mol Med. 2013. PMID: 24138818 Review.
Cited by
-
mRNA vaccines in the prevention and treatment of diseases.MedComm (2020). 2022 Aug 25;3(3):e167. doi: 10.1002/mco2.167. eCollection 2022 Sep. MedComm (2020). 2022. PMID: 36033422 Free PMC article. Review.
-
Clinical and immunological effects of mRNA vaccines in malignant diseases.Mol Cancer. 2021 Mar 15;20(1):52. doi: 10.1186/s12943-021-01339-1. Mol Cancer. 2021. PMID: 33722265 Free PMC article. Review.
-
An RNA toolbox for cancer immunotherapy.Nat Rev Drug Discov. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Nat Rev Drug Discov. 2018. PMID: 30190565 Review.
-
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix.Vaccines (Basel). 2019 Dec 6;7(4):209. doi: 10.3390/vaccines7040209. Vaccines (Basel). 2019. PMID: 31817794 Free PMC article.
-
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.Mol Ther Nucleic Acids. 2019 Sep 6;17:767-775. doi: 10.1016/j.omtn.2019.07.014. Epub 2019 Jul 30. Mol Ther Nucleic Acids. 2019. PMID: 31446119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials